This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

I. Preliminary Results for Relapse Rates

John M. Kane, MD; Arthur Rifkin, MD; Margaret Woerner, PhD; Gerard Reardon, MSW; Stavros Sarantakos, MD; David Schiebel, MD; Jorge Ramos-Lorenzi, MD

Arch Gen Psychiatry. 1983;40(8):893-896.

Abstract
• In an attempt to begin to establish minimum effective dosage requirements for the maintenance treatment of schizophrenia, we undertook a double-blind comparison of low-dose fluphenazine decanoate (1.25 to 5.0 mg/2 wk) with the standard-dose regimen (12.5 to 50.0 mg/2 wk) in outpatient schizophrenics. For the first 126 patients studied, cumulative relapse rates at one year for the low dose were 56% and for the standard dose 7%, a significant difference. Despite the fact that very little dyskinetic symptomatology developed in the sample as a whole, the low-dose treatment appeared to have a significant advantage in producing fewer early signs of tardive dyskinesia. Severity of relapse and total cumulative dosage were also considered.

Author Affiliations
From the Long Island Jewish—Hillside Medical Center, Glen Oaks, NY (Drs Kane, Woerner, Sarantakos, and Ramos-Lorenzi), and the Mt Sinai Medical Center, New York (Drs Rifkin and Schiebel and Mr Reardon).

Footnotes
Accepted for publication Nov 18, 1982.

Reprint requests to Long Island Jewish—Hillside Medical Center, PO Box 38, Glen Oaks, NY 11004 (Dr Kane).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical guideline recommendations for antipsychotic long-acting injections
Kane and Garcia-Ribera
Br. J. Psychiatry 2009;195:S63-S67.
ABSTRACT | FULL TEXT  

Commentary: Consensus Statement on Negative Symptoms
Kane
Schizophr Bull 2006;32:223-224.
FULL TEXT  

Maintenance Medication for Schizophrenia: Strategies for Dose Reduction
Schooler
Focus 2004;2:175-186.
ABSTRACT | FULL TEXT  

Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol
Lieberman et al.
Am. J. Psychiatry 2003;160:1396-1404.
ABSTRACT | FULL TEXT  

A Multidose Study of Haloperidol Decanoate in the Maintenance Treatment of Schizophrenia
Kane et al.
Am. J. Psychiatry 2002;159:554-560.
ABSTRACT | FULL TEXT  

Determining the optimal dose of haloperidol in first-episode psychosis
Oosthuizen et al.
J Psychopharmacol 2001;15:251-255.
ABSTRACT  

Comparative Effectiveness of Fluphenazine Decanoate Injections Every 2 Weeks Versus Every 6 Weeks
Carpenter et al.
Am. J. Psychiatry 1999;156:412-418.
ABSTRACT | FULL TEXT  

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia: The Effects of Dose Reduction and Family Treatment
Schooler et al.
Arch Gen Psychiatry 1997;54:453-463.
ABSTRACT  

Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia
Chakos et al.
Arch Gen Psychiatry 1996;53:313-319.
ABSTRACT  

Schizophrenia
Kane
NEJM 1996;334:34-42.
FULL TEXT  

Multiple-Family Groups and Psychoeducation in the Treatment of Schizophrenia
McFarlane et al.
Arch Gen Psychiatry 1995;52:679-687.
ABSTRACT  

Long-term Treatment for Lifetime Disorders?
Greden and Tandon
Arch Gen Psychiatry 1995;52:197-200.
ABSTRACT  

Fluphenazine vs Placebo Supplementation for Prodromal Signs of Relapse in Schizophrenia
Marder et al.
Arch Gen Psychiatry 1994;51:280-287.
ABSTRACT  

Identifying Risk Factors for Tardive Dyskinesia Among Long-term Outpatients Maintained With Neuroleptic Medications: Results of the Yale Tardive Dyskinesia Study
Morgenstern and Glazer
Arch Gen Psychiatry 1993;50:723-733.
ABSTRACT  

Intermittent vs Maintenance Medication in Schizophrenia: Two-Year Results
Herz et al.
Arch Gen Psychiatry 1991;48:333-339.
ABSTRACT  

Dosage of Haloperidol for Schizophrenia
Rifkin et al.
Arch Gen Psychiatry 1991;48:166-170.
ABSTRACT  

Dose of Fluphenazine, Familial Expressed Emotion, and Outcome in Schizophrenia: Results of a Two-Year Controlled Study
Hogarty et al.
Arch Gen Psychiatry 1988;45:797-805.
ABSTRACT  

Differential Effect of Low and Conventional Doses of Fluphenazine on Schizophrenic Outpatients With Good or Poor Information-Processing Abilities
Asarnow et al.
Arch Gen Psychiatry 1988;45:822-826.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT  

Low- and Conventional-Dose Maintenance Therapy With Fluphenazine Decanoate: Two-Year Outcome
Marder et al.
Arch Gen Psychiatry 1987;44:518-521.
ABSTRACT  

Selection of Neuroleptic Dosage
Teicher and Baldessarini
Arch Gen Psychiatry 1985;42:636-637.
ABSTRACT  

Tardive Dyskinesia in the Aged: Duration of Treatment Relationships
Toenniessen et al.
Arch Gen Psychiatry 1985;42:278-284.
ABSTRACT  

Costs and Benefits of Two Doses of Fluphenazine
Marder et al.
Arch Gen Psychiatry 1984;41:1025-1029.
ABSTRACT  

Anticholinergic Challenge and Neuroleptic Withdrawal: Changes in Dyskinesia and Symptom Measures
Gardos et al.
Arch Gen Psychiatry 1984;41:1030-1035.
ABSTRACT  

Standard v Optimal Dose
Ostow
Arch Gen Psychiatry 1984;41:726-727.
ABSTRACT  

Fluphenazine and Tardive Dyskinesia
Perenyi and Arato
Arch Gen Psychiatry 1984;41:727-727.
ABSTRACT